First recognized by the ancient Egyptians, the presentation and treatment of diabetes have dramatically evolved over the centuries [1] . Though the discovery of insulin 100 years ago changed the management of diabetes forever, most patients today are not insulin deficient, but overweight with a combination of insulin resistance and impaired insulin secretion [1] . While lifestyle changes can be very effective in improving glucose control, in the long-term most patients will eventually require medications to achieve adequate diabetic control [2] . For decades options for oral glucose lowering medications were limited, but in the past 25 years many more options have become available. The purpose of this article is to provide an overview of the existing oral and injectable (non-insulin) pharmacologic options available for the treatment of patients with type 2 diabetes.
Polonsky, K.S. (2012) The Past 200 Years in Diabetes. New England Journal of Medicine, 367, 1332-1340. https://doi.org/10.1056/NEJMra1110560
Feingold, K.R. (2020) Oral and Injectable (Non-Insulin) Pharmacological Agents for Type 2 Diabetes. In: Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Grossman, A., Hershman, J.M., Hofland, J., Kalra, S., Kaltsas, G., Koch, C., Kopp, P., Korbonits, M., Kovacs, C.S., Kuohung, W., Laferrère, B., McGee, E.A., McLachlan, R., Morley, J.E., New, M., Purnell, J., Sahay, R., Singer, F., Stratakis, C.A., Trence, D.L. and Wilson, D.P., Eds., Endotext [Internet], MDText.com, Inc., South Dartmouth, 1-78.
Quianzon, C.C. and Cheikh, I.E. (2012) History of Current Non-Insulin Medications for Diabetes Mellitus. Journal of Community Hospital Internal Medicine Perspectives, 2, 19081. https://doi.org/10.3402/jchimp.v2i3.19081
White, J.R. (2014) A Brief History of the Development of Diabetes Medications. Diabetes Spectrum, 27, 82-86. https://doi.org/10.2337/diaspect.27.2.82
Lazarus, B., Wu, A., Shin, J., et al. (2018) Association of Metformin Use with Risk of Lactic Acidosis across the Range of Kidney Function: A Community-Based Cohort Study. JAMA Internal Medicine, 178, 903-910. https://doi.org/10.1001/jamainternmed.2018.0292
Aroda, V., Edelstein, S., Goldberg, R., et al. (2016) Long-Term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. The Journal of Clinical Endocrinology and Metabolism, 101, 1754-1761. https://doi.org/10.1210/jc.2015-3754
(2019) Drugs for Type 2 Diabetes. The Medical Letter on Drugs and Therapeutics, 61, 169-178.
Tahrani, A., Barnett, A. and Bailey, C. (2016) Pharmacology and Therapeutic Implications of Current Drugs for Type 2 Diabetes Mellitus. Nature Reviews Endocrinology, 12, 566-592. https://doi.org/10.1038/nrendo.2016.86
Ferrannini, E. and De Fronzo, R.A. (2015) Impact of Glucose-Lowering Drugs on Cardiovascular Disease in Type 2 Diabetes. European Heart Journal, 36, 2288-2296. https://doi.org/10.1093/eurheartj/ehv239
Gilbert, M.P. and Pratley, R.E. (2020) GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Frontiers in Endocrinology (Lausanne), 11, 178. https://doi.org/10.3389/fendo.2020.00178
Holman, R.R., Bethel, M.A., Mentz, R.J., Thompson, V.P., Lokhnygina, Y., Buse, J.B., Chan, J.C., Choi, J., Gustavson, S.M., Iqbal, N., Maggioni, A.P., Marso, S.P., Öhman, P., Pagidipati, N.J., Poulter, N., Ramachandran, A., Zinman, B., Hernandez, A.F. and EXSCEL Study Group (2017) Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 377, 1228. https://doi.org/10.1056/NEJMoa1612917
Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Køber, L.V., Lawson, F.C., Ping, L., Wei, X., Lewis, E.F., Maggioni, A.P., McMurray, J.J., Probstfield, J.L., Riddle, M.C., Solomon, S.D., Tardif, J.C. and ELIXA Investigators (2015) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. The New England Journal of Medicine, 373, 2247. https://doi.org/10.1056/NEJMoa1509225
Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jódar, E., Leiter, L.A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M.L., Woo, V., Hansen, O., Holst, A.G., Pettersson, J., Vilsbøll, T. and SUSTAIN-6 Investigators (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine, 375, 1834. https://doi.org/10.1056/NEJMoa1607141
Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J., Riddle, M.C., Rydén, L., Xavier, D., Atisso, C.M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., Avezum, A., Basile, J., Chung, N., Conget, I., Cushman, W.C., Franek, E., Hancu, N., Hanefeld, M., Holt, S., Jansky, P., Keltai, M., Lanas, F., Leiter, L.A., Lopez-Jaramillo, P., Cardona Munoz, E.G., Pirags, V., Pogosova, N., Raubenheimer, P.J., Shaw, J.E., Sheu, W.H., Temelkova-Kurktschiev, T. and REWIND Investigators (2019) Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial. The Lancet, 394, 121.
Saito, T., Ohnuma, K., Suzuki, H., Dang, N.H., Hatano, R., Ninomiya, H. and Morimoto, C. (2013) Polyarthropathy in Type 2 Diabetes Patients Treated with DPP4 Inhibitors. Diabetes Research and Clinical Practice, 102, e8-e12. https://doi.org/10.1016/j.diabres.2013.07.010
Scirica, B., Braunwald, E., et al. (2014) Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. Circulation, 130, 1579-1588. https://doi.org/10.1161/CIRCULATIONAHA.114.010389
(2021) The Medial Letter: Dapagliflozin (Farxiga) for Chronic Kidney Disease. The Medical Letter on Drugs and Therapeutics, 63, 115.
Singh-Franco, D., Perez, A. and Harrington, C. (2011) The Effect of Pramlintide Acetate on Glycemic Control and Weight in Patients with Type 2 Diabetes Mellitus and in Obese Patients without Diabetes: A Systematic Review and Meta-Analysis. Diabetes, Obesity and Metabolism, 13, 169-180. https://doi.org/10.1111/j.1463-1326.2010.01337.x
Defronzo, R.A. (2011) Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes. Diabetes Care, 34, 789-794. https://doi.org/10.2337/dc11-0064
(2008) A New Indication for Colesevelam (Welchol). The Medical Letter on Drugs and Therapeutics, 50, 33.
Beysen, C., Murphy, E.J., Deines, K., et al. (2012) Effect of Bile Acid Sequestrants on Glucose Metabolism, Hepatic de Novo Lipogenesis, and Cholesterol and Bile Acid Kinetics in Type 2 Diabetes: A Randomised Controlled Study. Diabetologia, 55, 432-442. https://doi.org/10.1007/s00125-011-2382-3